Securing Continued CGT Uptake Is Multistakeholder Challenge

Jun 12
Jun 12, 2025

The advanced therapies market shows no signs of slowing, as scientific innovation continues to bring revolutionary new treatments out of the laboratory and onto the U.S. market. But some barriers to access, including the lack of patient caregiver support, payer hurdles and high costs, still remain and must be overcome if these agents are able to realize their potential and be even more impactful than they already are, according to a recent report from Cardinal Health.

Multiple advanced therapies — 22 cell and gene therapies (CGTs) and 22 ultra-specialty therapies — are available in the U.S., and that total is expected to more than quadruple by 2030. By that time, estimates find that more than 100,000 will have undergone treatment with them.
Read more
© 2025 MMIT

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.